JP2005511491A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005511491A5 JP2005511491A5 JP2003511855A JP2003511855A JP2005511491A5 JP 2005511491 A5 JP2005511491 A5 JP 2005511491A5 JP 2003511855 A JP2003511855 A JP 2003511855A JP 2003511855 A JP2003511855 A JP 2003511855A JP 2005511491 A5 JP2005511491 A5 JP 2005511491A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- concentration
- composition
- kit according
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 7
- 239000000243 solution Substances 0.000 claims 5
- 239000002904 solvent Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 2
- 230000001419 dependent Effects 0.000 claims 2
- 201000009273 endometriosis Diseases 0.000 claims 2
- 239000000262 estrogen Substances 0.000 claims 2
- 230000004720 fertilization Effects 0.000 claims 2
- 239000002474 gonadorelin antagonist Substances 0.000 claims 2
- 229940121381 gonadotrophin releasing hormone (GnRH) antagonists Drugs 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 230000002028 premature Effects 0.000 claims 2
- 230000001568 sexual Effects 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 230000002254 contraceptive Effects 0.000 claims 1
- 239000003433 contraceptive agent Substances 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
Claims (11)
- 一般式（１）：
Ac-DNal-DCpa-DPal-Ser-Aph(L-Hor)-DAph(CONH2)-Leu-Lys(iPr)-Pro-DAla-NH2（１）
で表されるＧｎＲＨ拮抗ペプチド又は医薬適合性のその塩の医薬適合性の溶媒中の溶液を含有し、前記ペプチドの溶液中の濃度が、前記ペプチドがゲル形態ではないが注射後ゲルを形成するよう少なくとも２５ｍｇ／ｍｌの濃度である、注射用医薬組成物。 - 溶液中の前記ペプチドの濃度が１２０ｍｇ／ｍｌ以下である、請求項１に記載の組成物。
- 溶液中の前記ペプチドの濃度が８０ｍｇ／ｍｌ以下である、請求項１又は２に記載の組成物。
- 請求項１で定義されたＧｎＲＨ拮抗ペプチド又はその塩を含有する第一コンポーネント及びそれらのための医薬適合性の溶媒を含有する第二コンポーネントを含むパーツの医薬キットであって、第一コンポーネント及び第二コンポーネントは混合され請求項１から３いずれかに記載の注射用医薬組成物を提供する医薬キット。
- 前記溶液中の前記ペプチドの濃度が１２０ｍｇ／ｍｌ以下である、請求項４に記載のキット。
- 前記ペプチドの濃度が８０ｍｇ／ｍｌ以下である、請求項５に記載のキット。
- 前記ペプチドの濃度が４０ｍｇ／ｍｌ以下である、請求項１から６のいずれかに記載の組成物又はキット。
- 前記溶媒が、水、又は溶媒の少なくとも９０重量％が水であるような水と第二の溶媒の混合物である、請求項１から７のいずれかに記載の組成物又はキット。
- 前記ペプチドがその塩酸塩又は酢酸塩の形態である、請求項１から８いずれかに記載の組成物又はキット。
- 良性前立腺過形成、前立腺癌、エストロゲン依存性乳癌、子宮内膜症又は性的早熟の治療のための、避妊薬としての使用又は体外受精プログラムにおける使用のための、又は性犯罪者の治療のための、請求項１から９のいずれかに記載の組成物又はキット。
- ペプチドが投与後自然にゲルを形成し、前記ゲルが少なくとも２週間にわたって該ペプチドを放出するデポー剤として働くような皮下又は筋肉内注射される医薬組成物であって、良性前立腺過形成、前立腺癌、エストロゲン依存性乳癌、子宮内膜症又は性的早熟の治療のための、避妊を提供するための、体外受精プログラムにおいて卵巣機能を制御するための、又は性犯罪者の治療のための医薬組成物を製造するための、一般式（１）：
Ac-DNal-DCpa-DPal-Ser-Aph(L-Hor)-DAph(CONH2)-Leu-Lys(iPr)-Pro-DAla-NH2（１）
で表されるＧｎＲＨ拮抗ペプチド又は医薬適合性のその塩の使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0117057.0A GB0117057D0 (en) | 2001-07-12 | 2001-07-12 | Pharmaceutical composition |
| GB0117057.0 | 2001-07-12 | ||
| PCT/GB2002/003116 WO2003006049A1 (en) | 2001-07-12 | 2002-07-08 | Gonadotropin releasing hormone antagonists in gel-forming concentrations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005511491A JP2005511491A (ja) | 2005-04-28 |
| JP2005511491A5 true JP2005511491A5 (ja) | 2007-05-24 |
| JP4845166B2 JP4845166B2 (ja) | 2011-12-28 |
Family
ID=9918396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003511855A Expired - Lifetime JP4845166B2 (ja) | 2001-07-12 | 2002-07-08 | ゲルを形成する濃度の性腺刺激ホルモン放出ホルモン拮抗物質 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20050245455A1 (ja) |
| EP (1) | EP1404357B1 (ja) |
| JP (1) | JP4845166B2 (ja) |
| AR (1) | AR036337A1 (ja) |
| AT (1) | ATE452648T1 (ja) |
| DE (1) | DE60234831D1 (ja) |
| DK (1) | DK1404357T3 (ja) |
| ES (1) | ES2338217T3 (ja) |
| GB (1) | GB0117057D0 (ja) |
| MY (1) | MY139203A (ja) |
| PT (1) | PT1404357E (ja) |
| UY (1) | UY27378A1 (ja) |
| WO (1) | WO2003006049A1 (ja) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| EP1565160B1 (de) | 2002-09-27 | 2014-01-22 | Æterna Zentaris GmbH | Darreichungsform für pharmazeutisch aktive peptide mit anhaltender wirkstofffreigabe und verfahren zu deren herstellung |
| EP3025722B1 (en) | 2003-10-03 | 2020-05-27 | Thorn BioScience, LLC | Process for the synchronization of ovulation for timed breeding without heat detection |
| GB0511269D0 (en) | 2005-06-02 | 2005-07-13 | Creative Peptides Sweden Ab | Sustained release preparation of pro-insulin C-peptide |
| JP5452230B2 (ja) * | 2006-12-21 | 2014-03-26 | ストライカー コーポレイション | 生物学的因子の結晶、高分子ゲルおよび粒子懸濁液を含む持続放出処方物 |
| JOP20090061B1 (ar) | 2008-02-11 | 2021-08-17 | Ferring Int Center Sa | طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH |
| PL2421545T3 (pl) | 2009-04-23 | 2018-05-30 | Jbs United Animal Health Ii Llc | Sposób i kompozycja do synchronizacji czasu inseminacji |
| MX2011011431A (es) * | 2009-05-01 | 2012-02-23 | Ferring Bv | Composicion para el tratamiento de cancer de prostata. |
| JO3550B1 (ar) * | 2009-05-01 | 2020-07-05 | Ferring Int Center Sa | مركب لمعالجة سرطان البروستاتا |
| TW201043221A (en) * | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
| US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| US9260480B2 (en) | 2010-10-27 | 2016-02-16 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| WO2013104745A1 (en) * | 2012-01-13 | 2013-07-18 | Ferring Bv | Pharmaceutical composition |
| MX364010B (es) | 2012-06-01 | 2019-04-11 | Ferring Bv | Manufactura de degarelix. |
| ITMI20121638A1 (it) | 2012-10-02 | 2014-04-03 | Marco Sbracia | Utilizzo di degarelix nel trattamento dell'endometriosi e di patologie ad essa correlate |
| ES2808409T3 (es) | 2012-11-28 | 2021-02-26 | United Ah Ii Llc | Método para sincronizar el tiempo de inseminación en cerdas primerizas |
| US10681261B2 (en) * | 2012-11-30 | 2020-06-09 | 3I Avi, Llc | Inspection system |
| TW201625218A (zh) * | 2014-04-18 | 2016-07-16 | Ｊｂｓ聯合動物保健有限責任公司 | 製造含ｇｎｒｈ凝膠之方法 |
| ES2878094T3 (es) * | 2017-01-30 | 2021-11-18 | Antev Ltd | Una composición que comprende al menos un antagonista de la GnRH |
| WO2019110688A1 (en) | 2017-12-05 | 2019-06-13 | Ferring B.V. | A composition comprising degarelix for use in the treatment of breast cancer |
| EP3560555A1 (en) | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US200486A (en) * | 1878-02-19 | Improvement in apparatus for attaching harness to the shafts | ||
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5516887A (en) * | 1991-04-25 | 1996-05-14 | Romano Deghenghi | Luteinizing hormone releasing hormone antagonist peptides |
| SI9300468A (en) * | 1992-10-14 | 1994-06-30 | Hoffmann La Roche | Injectable composition for the sustained release of biologically active compounds |
| US5506207A (en) * | 1994-03-18 | 1996-04-09 | The Salk Institute For Biological Studies | GNRH antagonists XIII |
| US5595760A (en) * | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| US5860957A (en) * | 1997-02-07 | 1999-01-19 | Sarcos, Inc. | Multipathway electronically-controlled drug delivery system |
| US5925730A (en) * | 1997-04-11 | 1999-07-20 | Ferring Bv | GnRH antagonists |
| US5821230A (en) * | 1997-04-11 | 1998-10-13 | Ferring Bv | GnRH antagonist decapeptides |
| FR2776520B1 (fr) * | 1998-03-25 | 2000-05-05 | Sod Conseils Rech Applic | Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation |
| US20020103131A1 (en) * | 2001-01-26 | 2002-08-01 | Jacobson Jill D. | Prevention of diabetes by administration of GnRH antagonists |
| GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
| AR042815A1 (es) * | 2002-12-26 | 2005-07-06 | Alza Corp | Dispositivo de suministro de agente activo que tiene miembros compuestos |
| EP1674082A1 (de) * | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
| EP1891964A1 (en) * | 2006-08-08 | 2008-02-27 | AEterna Zentaris GmbH | Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits |
| JOP20090061B1 (ar) * | 2008-02-11 | 2021-08-17 | Ferring Int Center Sa | طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH |
| US8105292B2 (en) * | 2008-02-11 | 2012-01-31 | Safety Syringes, Inc. | Reconstitution means for safety device |
| MX2011011431A (es) * | 2009-05-01 | 2012-02-23 | Ferring Bv | Composicion para el tratamiento de cancer de prostata. |
| TW201043221A (en) * | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
| US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
| EP2447276A1 (en) * | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| US9260480B2 (en) * | 2010-10-27 | 2016-02-16 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
| JO3755B1 (ar) * | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
| KR20140063602A (ko) * | 2011-07-15 | 2014-05-27 | 훼링 비.브이. | 피코설페이트 조성물을 투여하여 대장내시경의 시술 시기를 조절하는 방법 |
-
2001
- 2001-07-12 GB GBGB0117057.0A patent/GB0117057D0/en not_active Ceased
-
2002
- 2002-07-03 MY MYPI20022511A patent/MY139203A/en unknown
- 2002-07-08 PT PT02749000T patent/PT1404357E/pt unknown
- 2002-07-08 DK DK02749000.2T patent/DK1404357T3/da active
- 2002-07-08 JP JP2003511855A patent/JP4845166B2/ja not_active Expired - Lifetime
- 2002-07-08 EP EP02749000A patent/EP1404357B1/en not_active Expired - Lifetime
- 2002-07-08 US US10/483,325 patent/US20050245455A1/en not_active Abandoned
- 2002-07-08 US US10/380,623 patent/US20040038903A1/en not_active Abandoned
- 2002-07-08 DE DE60234831T patent/DE60234831D1/de not_active Expired - Lifetime
- 2002-07-08 WO PCT/GB2002/003116 patent/WO2003006049A1/en active Application Filing
- 2002-07-08 AT AT02749000T patent/ATE452648T1/de active
- 2002-07-08 ES ES02749000T patent/ES2338217T3/es not_active Expired - Lifetime
- 2002-07-11 UY UY27378A patent/UY27378A1/es not_active Application Discontinuation
- 2002-07-11 AR ARP020102599A patent/AR036337A1/es not_active Application Discontinuation
-
2008
- 2008-06-11 US US12/155,897 patent/US20090018085A1/en not_active Abandoned
-
2010
- 2010-10-08 US US12/901,270 patent/US20110053846A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005511491A5 (ja) | ||
| ES2222633T3 (es) | Terapia combinada para la profilaxis y/o el tratamiento de la hiperplasia prostatica benigna. | |
| JP4845166B2 (ja) | ゲルを形成する濃度の性腺刺激ホルモン放出ホルモン拮抗物質 | |
| ES2298570T3 (es) | Composiciones farmaceuticas que comprenden derivados de estetrol para el uso en la terapia del cancer. | |
| JP2719233B2 (ja) | 黄体形成ホルモン放出ホルモン拮抗ペプチド | |
| RU2007101304A (ru) | Модуляторы рецептора прогестерона, содержащие производные пиррол-оксиндола и применение | |
| MXPA02010066A (es) | Estratrienos sustituidos en 8beta-hidrocarbilo para uso como estrogenos selectivos. | |
| EA200970348A1 (ru) | Новые инъецируемые депо-композиции и способ получения таких композиций | |
| EP1877059B8 (en) | Micronized tanaproget and compostions containing same | |
| RU2008119462A (ru) | Конденсированное гетероциклическое производное, содержащая его лечебная композиция и ее применение в медицине | |
| EA200601724A1 (ru) | Новые композиции для местной доставки | |
| EP1782830A1 (en) | Preventive and/or remedy for lower urinary tract diseases containing ep4 agonist | |
| ES2206622T3 (es) | Uso de un analogo de hormona liberadora de gonadotropina. | |
| JP2009508808A5 (ja) | ||
| RU2004102507A (ru) | Композиция с регулируемым высвобождением и способ ее получения | |
| JP2005516904A5 (ja) | ||
| DE602006007453D1 (de) | Zusammensetzungen mit mikronisiertem tanaproget | |
| CA2381461A1 (en) | Lhrh antagonists having improved solubility properties | |
| Chengalvala et al. | GnRH agonists and antagonists in cancer therapy | |
| JP2522628B2 (ja) | ＧｎＲＨ類似体 | |
| WO2003020205A3 (en) | Non-mammalian gnrh analogs and uses thereof in regulation of fertility and pregnancy | |
| JPS60260594A (ja) | ＧｎＲＨ拮抗物質 | |
| JP2003026601A (ja) | 医薬組成物およびその製造法 | |
| HUP0102805A2 (hu) | Tienopiridin-származékok, előállításuk és alkalmazásuk | |
| Chi et al. | In vivo characterization of a novel GnRH (gonadotropin-releasing hormone) antagonist, LXT-101, in normal male rats |